



Adherium receives MHRA Registration Confirmation for Hailie® Sensor

Melbourne, Australia – 24 January 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, has received its Medicines and Healthcare products Regulatory Agency (MHRA) Registration confirmation as a medical devices manufacturer of inhaler dose sensors in the United Kingdom (UK).

The current generation of Hailie® sensor products are CE Marked and are available in the UK to patients working with National Health Service (NHS) - registered respiratory specialists and centres. The MHRA Registration enables continuous access to the UK market for Adherium’s Hailie® solution during and beyond the transition of the UK’s exit from the European Union.

“The UK is an important target market for Adherium’s products, with over 5 million people currently receiving treatment for Asthma and about 900 thousand diagnosed with Chronic Obstructive Pulmonary Disease (COPD),” said Adherium Chief Executive Officer, Rick Legleiter. “We are working with our patient-experience partner MD Healthcare to establish a UK-based advisory board and NHS working group to lead commercial pilots for our next-generation Hailie® sensor products. Receiving confirmation of our MHRA Registration ensures that our progress will continue through the withdrawal of the UK from the European Union.”

“In parallel with our current products we are also pursuing UKCA Mark for the UK and CE Mark in the European Union for new products to allow market access and continuity across the continent.”



Hailie® solution is a smart inhaler device that uses Bluetooth-enabled sensors to record and provide feedback to patients via the Hailie® app. Physicians can also monitor their patients remotely, by accessing their usage data and providing personalised healthcare guidance to reduce the severity and frequency of exacerbations, and the associated hospital admissions.

- ENDS -

About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com